These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28051241)

  • 1. Effects of omalizumab therapy on allergic rhinitis: a pilot study.
    Masieri S; Cavaliere C; Begvarfaj E; Rosati D; Minni A
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5249-5255. PubMed ID: 28051241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term omalizumab efficacy in allergic rhinitis.
    Cavaliere C; Begvarfaj E; Incorvaia C; Sposato B; Brunori M; Ciofalo A; Greco A; de Vincentiis M; Masieri S
    Immunol Lett; 2020 Nov; 227():81-87. PubMed ID: 32798500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress of monoclonal antibody omalizumab in the treatment of allergic rhinitis].
    Qiu X; Wang H
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Feb; 50(2):166-8. PubMed ID: 25916543
    [No Abstract]   [Full Text] [Related]  

  • 4. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
    Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab: a monoclonal anti-IgE antibody.
    Belliveau PP
    MedGenMed; 2005 Jan; 7(1):27. PubMed ID: 16369332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
    J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in asthma: approval and postapproval experience.
    Chiang DT; Clark J; Casale TB
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):3-16. PubMed ID: 16222080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody.
    Berger WE
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S29-32. PubMed ID: 16722329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
    Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
    Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
    Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab, an anti-immunoglobulin E antibody: state of the art.
    Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E
    Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.
    Tsabouri S; Tseretopoulou X; Priftis K; Ntzani EE
    J Allergy Clin Immunol Pract; 2014; 2(3):332-40.e1. PubMed ID: 24811026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab : other indications and unanswered questions.
    Mankad VS; Burks AW
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A next-generation anti-IgE monoclonal?
    Roberts G
    Clin Exp Allergy; 2016 Nov; 46(11):1370-1371. PubMed ID: 27790844
    [No Abstract]   [Full Text] [Related]  

  • 20. What is new in antiimmunoglobulin E asthma therapy.
    Berger WE
    Allergy Asthma Proc; 2005; 26(6):428-34. PubMed ID: 16541964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.